AFT Pharmaceuticals (ASX:AFP) Total Long-Term Assets: A$57.1 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

ASX:AFP AFT Pharmaceuticals Ltd ASX:AFP
90 GF Score
Price A$3.19
GF Value A$3.39
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is AFT Pharmaceuticals Total Long-Term Assets?

AFT Pharmaceuticals ASX:AFP 90 Total Long-Term Assets is A$57.1 Mil as of Mar. 2026. GuruFocus rates ASX:AFP with a GF Score™ of 90/100 and a GF Value™ of A$3.39 (Fairly Valued). The stock has 4 warning signs investors should review.

Total Long-Term Assets includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets. AFT Pharmaceuticals's Total Long-Term Assets for the quarter that ended in Mar. 2026 was A$57.1 Mil.

AFT Pharmaceuticals Total Long-Term Assets Related Terms

AFT Pharmaceuticals Total Long-Term Assets Historical Data

* Premium members only.

The historical data trend for AFT Pharmaceuticals's Total Long-Term Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AFT Pharmaceuticals Total Long-Term Assets Chart

AFT Pharmaceuticals Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Total Long-Term Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 41.18 49.71 55.22 55.88 57.06

AFT Pharmaceuticals Semi-Annual Data
Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Total Long-Term Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 55.22 56.17 55.88 57.64 57.06
ASX:AFP
90GF Score
AFT Pharmaceuticals Ltd ASX:AFP
Total Long-Term Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

AFT Pharmaceuticals Total Long-Term Assets Calculation

Total Long-Term Assets are the sum of the carrying amounts of all assets that are expected to be realized in cash, sold or consumed longer than one year. It includes Investments And Advances, Intangible Assets, Property, Plant and Equipment and Other Long Term Assets.

Frequently Asked Questions Learn more about Total Long-Term Assets →
What does a Total Long-Term Assets of A$57.1 Mil mean?
AFT Pharmaceuticals (ASX:AFP) has a Total Long-Term Assets of A$57.1 Mil as of Mar. 2026. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on AFT Pharmaceuticals and its competitors.
Is AFT Pharmaceuticals' Total Long-Term Assets too high?
AFT Pharmaceuticals' current Total Long-Term Assets is A$57.1 Mil. Overall, AFT Pharmaceuticals has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does AFT Pharmaceuticals' Total Long-Term Assets compare to ZTS and UTHR?
AFT Pharmaceuticals' Total Long-Term Assets of A$57.1 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Long-Term Assets for a Drug Manufacturers company?
A good Total Long-Term Assets depends on the Drug Manufacturers industry context. However, Total Long-Term Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Long-Term Assets mean?
A high Total Long-Term Assets can signal that a stock is expensive relative to its fundamentals. Total Long-Term Assets are assets that are expected to be realized in cash, sold or consumed longer than one year. View historical data on AFT Pharmaceuticals and its competitors. AFT Pharmaceuticals's current Total Long-Term Assets is A$57.1 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AFT Pharmaceuticals stock overvalued right now?
Based on GuruFocus' analysis, AFT Pharmaceuticals (ASX:AFP) is currently considered Fairly Valued. The stock's GF Value™ is A$3.39, compared to a current price of A$3.19 — trading 5.9% below its estimated fair value. The current Total Long-Term Assets is A$57.1 Mil. AFT Pharmaceuticals' overall GF Score™ is 90/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Long-Term Assets calculated?
Total Long-Term Assets is calculated from a company's financial statements. For AFT Pharmaceuticals (ASX:AFP), the current Total Long-Term Assets is A$57.1 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AFT Pharmaceuticals (ASX:AFP) Overvalued in 2026?

Based on GuruFocus' analysis, AFT Pharmaceuticals stock appears to be undervalued. The current stock price of A$3.19 is trading 5.9% below its estimated GF Value™ of A$3.39. GuruFocus considers AFT Pharmaceuticals to be Fairly Valued.

Key valuation signals for ASX:AFP:

  • Total Long-Term Assets: A$57.1 Mil
  • GF Value™: A$3.39 vs. price of A$3.19 (5.9% below fair value)
  • GF Score™: 90/100 with 4 warning signs

No single metric tells the full story. See the ASX:AFP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AFT Pharmaceuticals Business Description

Other Exchanges AFT:New Zealand
Address 129 Hurstmere Road, Level 1, Takapuna, Auckland, NTL, NZL, 0622
AFT Pharmaceuticals Ltd is a pharmaceutical distributor and developer of pharmaceutical intellectual property. Some of the products of the organization are Maxigesic dose forms, Capsaicin creams, Crystaderm, Kiwisoothe, Micolette, and others. The group has four operating segments based on geographical location being Australia, New Zealand, Asia, and the Rest of the world. It generates the majority of the revenue from Australia, which includes the sales and distribution activity relating to the Australian market.
90GF Score

Get the complete analysis for ASX:AFP

Total Long-Term Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$3.19
Price
A$3.39
GF Value